Coin flip: Top an­a­lyst gives Amy­lyx ALS drug a 50% chance at ap­proval as rare sec­ond ad­comm ap­proach­es

It’s late Au­gust. We’re in the dog days of sum­mer. Seem­ing­ly every­one in bio­phar­ma has re­port­ed their first-half earn­ings and tak­en va­ca­tion, get­ting some R&R be­fore things ramp back up fol­low­ing La­bor Day.

But one of the more an­tic­i­pat­ed Q2 events will oc­cur al­most im­me­di­ate­ly af­ter the hol­i­day — the un­usu­al sec­ond ad­comm for Amy­lyx Phar­ma­ceu­ti­cals’ ex­per­i­men­tal ALS drug. And at least one an­a­lyst ap­pears to be fore­go­ing time off (at least for now) to try and read the tea leaves ahead of the Sept. 7 hear­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER